Cancer: Drugs

Department of Health and Social Care written question – answered on 4th March 2020.

Alert me about debates like this

Photo of Jonathan Reynolds Jonathan Reynolds Shadow Economic Secretary (Treasury)

To ask the Secretary of State for Health and Social Care, what steps he is taking to tackle delays in approval by NICE for the use of innovative cancer drugs on the NHS.

Photo of Jo Churchill Jo Churchill The Parliamentary Under-Secretary for Health and Social Care

New arrangements for the assessment and adoption of new cancer drugs were introduced in 2016 to help improve patient access to new cancer drugs, including through the Government established Cancer Drugs Fund.

The National Institute for Health and Care Excellence is now committed to publishing final guidance within 90 days of a new cancer drug receiving its licence and aims to publish its draft recommendation before a licence is granted. The forecasted mean time from a new cancer drug receiving its licence to published final guidance in 2020/21 is now 1.5 months which is a reduction of 13.5 months from 2012/13. The speed of appraisal output is affected by appeals, late referrals, additional committee meetings and companies negotiating revised timing of appraisals.

Does this answer the above question?

Yes1 person thinks so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.